In a notice issued to the London Stock Exchange on the company’s share price movement, AstraZeneca (AZN) stated: “As a matter of policy, we do not comment on speculative media reports including those related to ongoing investigations in China. If requested, we will fully cooperate with the Chinese authorities. We continue to deliver our life changing medicines to patients in China and our operations are ongoing.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AZN:
- AstraZeneca China an overhang, but feels ‘overdone,’ says BMO Capital
- Chinese authorities probing ‘dozens’ of AstraZeneca executives, Yicai reports
- AstraZeneca call volume above normal and directionally bullish
- Eli Lilly (NYSE:LLY) Stock Falls as Competitors Report Progress
- AstraZeneca oral GLP1 looks to be trailing Eli Lilly’s, says Deutsche Bank